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Abstract
Background: Infectious salmon anaemia (ISA) virus (ISAV), an important pathogen of fish that causes disease
accompanied by high mortality in marine-farmed Atlantic salmon, is the only species in the genus Isavirus, one of
the five genera of the Orthomyxoviridae family. The Isavirus genome consists of eight single-stranded RNA species,
and the virions have two surface glycoproteins; haemagglutinin-esterase (HE) protein encoded on segment 6 and
fusion (F) protein encoded on segment 5. Based on the initial demonstration of two 5'-coterminal mRNA
transcripts by RT-PCR, ISAV genomic segment 7 was suggested to share a similar coding strategy with segment
7 of influenza A virus, encoding two proteins. However, there appears to be confusion as to the protein sizes
predicted from the two open reading frames (ORFs) of ISAV segment 7 which has in turn led to confusion of the
predicted protein functions. The primary goal of the present work was to clone and express these two ORFs in
order to assess whether the predicted protein sizes match those of the expressed proteins so as to clarify the
coding assignments, and thereby identify any additional structural proteins of ISAV.
Results: In the present study we show that ISAV segment 7 encodes 3 proteins with estimated molecular masses
of 32, 18, and 9.5 kDa. The 18-kDa and 9.5-kDa products are based on removal of an intron each from the primary
transcript (7-ORF1) so that the translation continues in the +2 and +3 reading frames, respectively. The segment
7-ORF1/3 product is variably truncated in the sequence of ISAV isolates of the European genotype. All three
proteins are recognized by rabbit antiserum against the 32-kDa product of the primary transcript, as they all share
the N-terminal 22 amino acids. This antiserum detected a single 35-kDa protein in Western blots of purified virus,
and immunoprecipitated a 32-kDa protein in ISAV-infected TO cells. Immunofluorescence staining of infected
cells with the same antiserum revealed the protein(s) to be localized in the cytoplasm. Vaccination of farmed
Atlantic salmon with the 32-kDa protein resulted in a higher survival rate than what was attainable with the HE
protein, albeit a moderate protection against the low ISAV challenge.
Conclusion: Collectively, our observations suggest that the product of ISAV segment 7 primary transcript (7-
ORF1) is a structural protein. The 18-kDa (7-ORF1/2) protein is identified as the putative ISAV nuclear export
protein based on the presence of nuclear export signals. The function of the 9.5-kDa (7-ORF1/3) protein is not
presently known.
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Background
Infectious salmon anaemia (ISA) virus (ISAV) is an
important pathogen of fish that causes disease accompa-
nied by high mortality in marine-farmed Atlantic salmon.
The disease has caused severe economic losses to the
salmon-farming industry in several countries in the north-
ern hemisphere including Norway, Faroes Islands (Den-
mark), USA and Canada, and confirmed positive
diagnostic results for ISA are reportable to the "Office
International des Epizooties", OIE [1]. It is generally
accepted that vaccination is the best option for control of
the disease in marine-farmed fish, but the presently avail-
able whole virus inactivated vaccine that is used in Maine,
USA, and Canada does not fully protect against the virus
[2].
ISAV is the only species in the genus Isavirus, which is one
of five genera of the Orthomyxoviridae family [3]. Viruses in
the genus Isavirus contain a segmented genome of eight
single-stranded RNA species of negative sense ranging in
length from 1.0 to 2.4 kb with a total molecular size of
approximately 14.3–14.5 kb [4,5]. Different researchers
have collectively sequenced all eight RNA genomic seg-
ments of ISAV. Assignments of viral proteins to these seg-
ments have been predominantly based on amino acid
composition, computer-assisted motif identification, and
counterparts of influenza viruses. It is becoming increas-
ingly clear that the gene-coding assignments of the ISAV
genome differ from those of other orthomyxoviruses
[1,6]. Thus the enveloped particles have a diameter of 90–
140 nm with two surface glycoproteins; haemagglutinin-
esterase (HE) protein, a receptor binding haemagglutinin
with receptor destroying enzyme activity demonstrated to
be an acetylesterase [7,8] encoded on segment 6, and
fusion protein (F) [9] encoded on segment 5. Sequence
analysis of several ISAV isolates on the eight segments
consistently reveals two genotypes, one European and one
North American.
The ISAV segment 7 was originally assumed to encode two
putative matrix proteins [10], analogous to M1 and M2
proteins of segment 7 of influenza A virus [11]. In that
proposed gene expression model for ISAV segment 7, the
putative M2 protein shared the first 22 amino terminal
residues including the initiating methionine of the M1,
but with the removal of the 526 nucleotide intron and
resultant frameshift, the translation continued in the +2
reading frame terminating downstream of the M1 exon
[10]. However, the M1 and M2 proteins predicted to have
molecular weights of 34.1 kDa and 17.7 kDa, respectively,
were not verified, although M2 was suggested as the
fusion protein because of its similarity (38% identity) to
the fusion glycoprotein F of rinderpest virus [10]. Biering
et al. [12] expressed segment 7 open reading frame (ORF)
1 in Escherichia coli and prepared rabbit antibodies to the
expressed protein. Because the segment 7 ORF1 protein
did not react with whole ISAV antiserum, it was consid-
ered to be nonstructural or a minor structural protein
[12]. In subsequent studies, these authors reported the 7-
ORF1 product to be an interferon-signalling antagonist, a
function similar to that of the non-structural (NS1) pro-
tein encoded by segment 8 of influenza A virus [13]. It is
apparent that the structural protein profile of ISAV has not
been conclusively determined. This information is essen-
tial in order to understand the viral proteins that are
important in inducing protective immune responses in
fish and/or viral proteins that could be targeted in viral
diagnosis.
The primary goal of the present work was to clone and
express the two ORFs in ISAV segment 7 in order to assess
whether the protein sizes predicted from the ORFs match
those of the expressed proteins so as to clarify the coding
assignments, and thereby identify any additional struc-
tural proteins of ISAV.
Results and Discussion
In-vitro expression of ISAV proteins
All the eight RNA genomic segments of ISAV have been
sequenced, but it is not known if the protein sizes pre-
dicted from all the ORFs match those of the expressed pro-
teins or if all the viral structural proteins of ISAV can be
accounted for. In particular, there appears to be confusion
as to the protein sizes predicted from two ORFs of seg-
ment 7 which has in turn led to confusion of the predicted
protein functions. For example, Biering et al. [12] were
unable to identify a protein of the size predicted by ORF1,
the largest ORF of segment 7, in Western blots using
whole ISAV antiserum, leading them to conclude that it
was a non-structural viral protein. To address this ques-
tion, 10 different constructs representing the known ORFs
in the eight RNA genomic segments (1 each for RNA seg-
ments 1–6 and 2 each for RNA segments 7 and 8) were
made in pCR®II-TOPO® vector (Table 1). They were then
expressed in an in vitro T7/SP6 coupled transcription-
translation system and the gene products were correlated
to metabolically labeled ISAV proteins synthesized in
ISAV-infected cells. Protein products were monitored by
SDS-PAGE as shown in Figure 1, which represents a direct
comparison between the in vitro translation products and
the proteins synthesized in ISAV-infected TO cells. Three
proteins which appeared as prominent bands above the
background bands of cellular proteins of ISAV-infected
cell lysates (77 kDa, 37 kDa and 23.5 kDa) (Fig. 1A and
1B) were unambiguously assigned to viral RNA segments
3, 6, and 8 ORF2, and corresponded to nucleoprotein
(NP), HE, and matrix (M) proteins, respectively. A 71 kDa
band correlating with the product of segment 4 (lane 6)
was also weakly visible in ISAV-infected cells at 96 hr
(lane 4), hence the mark on Figure 1A. Our results con-Virology Journal 2007, 4:34 http://www.virologyj.com/content/4/1/34
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firmed that the observed molecular mass of the HE pro-
tein in ISAV-infected cells is 37 kDa (Fig. 1A, lanes 2–4),
as reported previously by Griffiths et al. [14]. The HE pro-
tein in purified virus particles has higher molecular mass
[7] probably resulting from post-translational modifica-
tions such as glycosylation.
To eliminate the background bands in ISAV-infected cell
preparations and in vitro translation products and identify
all the structural viral proteins, we carried out immuno-
precipitation analysis with rabbit antiserum against puri-
fied whole ISAV. Analysis of the immunoprecipitates
revealed up to six major protein bands in ISAV-infected
TO cells consisting of the 77 kDa, 44.5 kDa, 37 kDa, 30.5
kDa, 23.5 kDa, and 16.5 kDa proteins, with the most
intense bands being of the 77 kDa and 23.5 kDa proteins.
The 77 kDa, 44.5 kDa, 37 kDa, and 23.5 kDa proteins co-
migrated with the gene products of segments 3, 5, 6, and
8 ORF2, respectively (Figs 2A and 2B), which in purified
ISAV correspond to NP, F, HE, and M proteins, respec-
tively. The 30.5 and 16.5 kDa proteins in immunoprecip-
itates of ISAV-infected TO cells corresponded to segment
7 ORFs 1 and 2 products, of 32.5 and 16.0 kDa respec-
tively, which were also immunoprecipitated with whole
ISAV antiserum (Fig. 2B). Indeed in gels ran with different
sets of protein molecular weight standards, the corre-
sponding immunoprecipitates of ISAV-infected TO cells
were 32 and 18 kDa, respectively, indicating that one or
both segment 7 products are components of ISAV virions.
We previously reported a 29–30 kDa protein which was
immunoprecipitated in different infected TO cell lysates
for 5 different ISAV strains using the same antiserum
against purified ISAV as in the present study [15]. But oth-
ers reported the segment 7 ORF 1 encoded protein not to
react with ISAV antiserum, and it was concluded that it
was either non-structural or a minor structural protein
[12]. However, the fact that both segment 7 ORFs 1 and 2
products could be immunoprecipitated with antiserum
against purified ISAV in the present study indicates that
they are components of ISAV virions. We conclude from
these experiments that (a) the four major polypeptides of
71 kDa, 53 kDa, 43 kDa, and 24 kDa, observed in gel elec-
trophoresis of purified ISAV [16,17] correspond to prod-
ucts of segments 3, 5, 6, and 8-ORF2, respectively, and (b)
only the products of segments 5, 6, and 7-ORF1 are glyc-
osylated when expressed in presence of canine micro-
somal membranes, suggesting that the 7-ORF1 product
could also be a membrane protein. The segments 5 and 6
products correspond to the two previously reported sur-
face glycoproteins of ISAV, the F protein [9] and the HE
protein [7], respectively.
Further characterization of the protein encoded by 
segment 7 ORF 1
To determine if the segment 7 ORF 1 protein is one of the
integral membrane proteins of ISAV, its amino acid
sequence was examined for hydrophobic membrane
attachment sequences or transmembrane motifs using the
TMHMM prediction algorithm, version 2.0 [18], which
showed it not to be a transmembrane protein. A similar
observation was previously made by Ritchie et al. [10].
The sequence analysis of the segment 7 ORF 1 protein,
however, revealed that it has four predicted N-myristoyla-
tion sites, at positions 69GSCVSF74,  203GLKGSW208,
Table 1: The oligonucleotide primers used in amplification of viral cDNA and construction of transcription vectors for ISAV genes
Designated name and (size) of primer Sequence Nucleotide position, and GenBank Accession number
ISAV SEG1p1 FOR (26 mer) GTCGACCAGCTAAGAATGGACTTTAT 1–20, AY168787
ISAV SEG1p4 REV (28 mer) GGTACCTTAAACACCATATTCATCCATC 1634–1685, AF404347
ISAV SEG2p5 FOR (28 mer) GTCGACATAACCATGGAAACTCTAGTAG 29–50, AF404346
ISAV SEG2p8 REV (28 mer) GGTACCTCAAACATGCTTTTTCTTCTTA 2140–2161, AF404346
ISAV SEG3 FOR (18 mer) ATGGCCGATAAAGGTATG 49–66, AF404345
ISAV SEG3 REV (18 mer) CTAAATGTCAATGTCTTC 1882–1899, AF404345
ISAV SEG4 FOR (20 mer) ATGGATAACCTCCGTGAATG 5–24, AF404344
ISAV SEG4 REV (18 mer) TCATTGGGTACTGACTGC 1724–1741, AF404344
ISAV SEG5 FOR (21 mer) ATGGCTTTTCTAACAATTTTA 9–29, AF404343
ISAV SEG5 REV (21 mer) CTACCCTTTAGTAATGTACAG 1368–1388, AF404343
ISAV SEG6 FOR (25 mer) ATGGCACGATTCATAATTTTATTCC 20–44, AJ276859
ISAV SEG6 REV (24 mer) GTTGTCTTTCTTTCATAATCAAGC 1181–1204, AJ276859
ISAV SEG7 (ORF1) FOR (23 mer) ATGGATTTCACCAAAGTGTATGG 22–44, AF328627
ISAV SEG7 (ORF1) REV (23 mer) TCACATTCTGAAGTGAAGTCCAG 902–924, AF328627
ISAV SEG7 (ORF2) FOR (82 mer) ATGGATTTCACCAAAGTGTATGGT 22–84/611–629, AF328627
GTGCTGGTTGACCAACTAAAACTT
CACGGAAAAGACAAGGTGGCTTCT TTCCTGTCGG
ISAV SEG7 (ORF2)_REV (24 mer) CATCTTTAGTTCTCATTACAAATG 1009–1032, AF328627
ISAV SEG8 (ORF1) FOR (18 mer) ATGAACGAATCACAATGG 12–29, AF312317
ISAV SEG8 (ORF1) REV (18 mer) TTACTTCAGGTACCCCAG 585–602, AF312317
ISAV SEG8 (ORF2) FOR (21 mer) ATGGATACAAAAACATCTACC 26–46, AF312317
ISAV SEG8 (ORF2) REV (21 mer) ATTTATTGTATAGAGTCCTCC 733–753, AF312317
The underlined sequences in segments 1 and 2 primers correspond to Sal I site: GTCGAC and Kpn I site: GGTACCVirology Journal 2007, 4:34 http://www.virologyj.com/content/4/1/34
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Autoradiograph of SDS-PAGE of expressed proteins labeled with [35S]methionine in a coupled in vitro TNT System with the dif- ferent constructs in pCR®II-TOPO® plasmid and in TO cells infected with ISAV Figure 1
Autoradiograph of SDS-PAGE of expressed proteins labeled with [35S]methionine in a coupled in vitro TNT 
System with the different constructs in pCR®II-TOPO® plasmid and in TO cells infected with ISAV. The 
prestained protein standards (Invitrogen Life Sciences) are drawn in on the left while corresponding molecular masses of the 
ISAV proteins seen above the background of cellular proteins are indicated on the right. (A) Lanes 1 to 8 contain radiolabeled 
proteins synthesized in uninfected TO cells, ISAV-infected TO cells at 24, 48 and 96 hr post-infection, and in TNT System with 
constructs of ORFs in ISAV segments 3–6, respectively. Lanes 9 and 10 contain radiolabeled proteins synthesized in TNT Sys-
tem in presence of canine microsomes with constructs of ORFs in ISAV segments 5 and 6, respectively. A band correlating 
with the product of segment 4 was visible in ISAV-infected cells at 96 hrs (lane 4), and is therefore indicated on the right. (B) 
Lanes 1 to 8 contain radiolabeled proteins synthesized in uninfected TO cells, ISAV-infected TO cells at 24, 48 and 96 hr post-
infection, and in TNT System with constructs of ISAV segment 7 ORFs 1 and 2 and segment 8 ORFs 1 and 2, respectively. 
Lanes 9 to 12 contain radiolabeled proteins synthesized in TNT System in presence of canine microsomes with constructs of 
ISAV segment 7 ORFs 1 and 2 and segment 8 ORFs 1 and 2, respectively.Virology Journal 2007, 4:34 http://www.virologyj.com/content/4/1/34
Page 5 of 15
(page number not for citation purposes)
206GSWGGW211, and 271GCTGSA276. Such a signal pep-
tide(s) would allow the predicted protein to be associated
with the membrane even in the absence of a transmem-
brane motif, making it a putative monotopic integral
membrane protein [19].
In order to more specifically characterize the segment 7
ORF 1 protein, a GST-fusion construct of segment 7 ORF1
(designated GST-7 ORF1) was expressed in E. coli for pur-
poses of purifying it and using it to immunize a rabbit for
preparation of antiserum, and for use in fish vaccination
experiments. Expression in E. coli resulted in production
of the GST-fusion protein in insoluble inclusion bodies
despite the reduction of the incubation temperature to
15°C after IPTG (isopropyl-β-D-thiogalactoside) induc-
tion of bacterial cultures. Prior to use in the rabbit immu-
nization and the fish vaccination experiments, the
inclusion body fraction was extracted three more times
with the lysis buffer, and was then resuspended in
Arginine buffer. This buffer did not solubilize the inclu-
sion bodies but prevented aggregation, allowing the inclu-
sion bodies to remain in suspension for liquid handling.
Both the rabbit polyclonal antiserum prepared against the
GST-7 ORF1 fusion protein and the rabbit antiserum
against whole purified ISAV were applied separately to
Western blots of purified ISAV, GST-7ORF1, and GST pro-
tein alone. Figure 3A shows a Coomassie blue-stained gel
of these samples. The rabbit antiserum to whole ISAV was
specific for the purified virus (Fig. 3B, lane 1) and did not
react with the GST protein (Fig. 3B, lane 2). The rabbit
antiserum to GST-7ORF1 fusion protein reacted specifi-
cally with a single 35-kDa viral protein in Western blots of
purified virus (Fig. 3C, lane 1), confirming that segment 7
ORF1 encodes a structural protein of ISAV. This antiserum
also reacted with the GST protein (Fig. 3C, lane 2).
In order to demonstrate the sub-cellular localization of
the segment 7 ORF1 protein, as well as to confirm the viral
specificity of the rabbit antiserum prepared against GST-
7ORF1 fusion protein, both uninfected and infected cell
cultures (TO, ASK-2 and CHSE-214 cell lines) on slide
flasks were fixed at 1, 3, and 6 days post-inoculation and
used in immunofluorescence staining with the antiserum.
The results on the infected cell monolayers are summa-
rized in Table 2, and also presented in Figure 4, showing
that the segment 7 ORF1 protein localizes in the cyto-
plasm. In contrast, no reaction was observed with the
uninfected TO, ASK-2 and CHSE-214 cell samples (data
not shown), indicating that the immunoreactive protein
was of ISAV origin.
Vaccination of Atlantic salmon with the GST-7 ORF1 
fusion protein protects against ISAV-induced mortality
In order to determine if the segment 7 ORF 1 protein is
important in inducing protective immune responses in
Autoradiograph of SDS-PAGE of expressed proteins labeled  with [35S]methionine in a coupled in vitro TNT System with  the different constructs in pCR®II-TOPO® plasmid and in TO  cells infected with ISAV as in Fig. 1, immunoprecipitated with  rabbit antiserum to purified ISAV Figure 2
Autoradiograph of SDS-PAGE of expressed proteins 
labeled with [35S]methionine in a coupled in vitro 
TNT System with the different constructs in pCR®II-
TOPO® plasmid and in TO cells infected with ISAV 
as in Fig. 1, immunoprecipitated with rabbit antise-
rum to purified ISAV. The prestained protein standards 
(Invitrogen Life Sciences) are drawn in on the left while cor-
responding molecular masses of immunoprecipitated ISAV 
proteins are indicated on the right. (A) Lanes 1 to 8 contain 
radiolabeled proteins synthesized in uninfected TO cells, 
ISAV-infected TO cells at 24, 48 and 96 hr post-infection, and 
in TNT System with constructs of ORFs in ISAV segments 3–
6, respectively. (B) Lanes 1 to 8 contain radiolabeled pro-
teins synthesized in uninfected TO cells, ISAV-infected TO 
cells at 24, 48 and 96 hr post-infection, and in TNT System 
with constructs of ISAV segment 7 ORFs 1 and 2 and seg-
ment 8 ORFs 1 and 2, respectively.Virology Journal 2007, 4:34 http://www.virologyj.com/content/4/1/34
Page 6 of 15
(page number not for citation purposes)
fish, a vaccine assay was performed. The vaccine prepara-
tions tested consisted of the following antigens emulsified
in mineral oil (1) GST-7 ORF1 fusion protein in insoluble
inclusion bodies, (2) GST-HE fusion protein in insoluble
inclusion bodies, and (3) GST-E. coli lysate. In this partic-
ular study, the high challenge dose of 106.1 TCID50/fish
was used to model protection against acute disease (i.e.,
ISA mortality starting between 10 and 13 days post-inoc-
ulation and lasting 9–15 days); and the low challenge
dose of 103.5 TCID50/fish was used to model protection
Analysis of purified ISAV and GST proteins in Western blots Figure 3
Analysis of purified ISAV and GST proteins in West-
ern blots. The prestained protein standards (Invitrogen Life 
Sciences) are drawn in on the left while corresponding 
molecular masses of proteins are indicated on the right. (A) 
Coomassie blue-stained gel of the proteins. Lane M contains 
the prestained protein standards. Lanes 1 to 3 contain puri-
fied ISAV, GST-7ORF1 fusion protein inclusion bodies, and 
GST protein, respectively. (B) Western blots reacted with 
rabbit antiserum to whole ISAV. Lanes 1 and 2 contain puri-
fied ISAV and GST protein, respectively. (C) Western blots 
reacted with rabbit antiserum to GST-7ORF1 fusion protein. 
Lanes 1 and 2 contain purified ISAV and GST protein, respec-
tively.
Immunofluorescence of ASK-2 cell cultures infected with  ISAV and stained with rabbit antiserum to GST-7ORF1 fusion  protein Figure 4
Immunofluorescence of ASK-2 cell cultures infected 
with ISAV and stained with rabbit antiserum to GST-
7ORF1 fusion protein. Upper panel are cells 1 day post-
inoculation with ISAV. Lower panel are cells 6 days post-
inoculation with ISAV.Virology Journal 2007, 4:34 http://www.virologyj.com/content/4/1/34
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against chronic/protracted disease (i.e., ISA mortality last-
ing longer and/or starting later than in acute disease) [20].
Table 3 summarizes the relative percent survival (RPS),
and Figure 5 shows the cummulative percent mortalities
for the different vaccine preparations. The level of protec-
tion engendered by the GST-7 ORF1 fusion protein prep-
aration was comparable to that of the GST-HE fusion
protein preparation at the high challenge dose level. How-
ever, the GST-7 ORF1 fusion protein preparation resulted
in a higher survival rate than what was attainable with the
GST-HE fusion protein preparation, although it was only
a moderate protection against the low ISAV challenge
dose. Others who have tested recombinant ISAV HE vac-
cines have also reported only moderate protection result-
ing in 39.5–60.5% RPS after ISAV challenge [21]. Because
only viral structural proteins are normally used as vaccine
agents, we consider the immunizing properties of the
GST-7 ORF1 fusion protein when administered as a vac-
cine in this study, as further evidence indicating that the
segment 7-ORF1 product is a structural protein.
Characterization of ISAV segment 7 ORF1/2 protein
In a separate study in our laboratory, not described in this
paper, the segment 7 ORF1/2 (18-kDa) product showed
specific strong binding with caspase-8; also weaker bind-
ing reactions were noted with segments 1 ORF and 7
ORF1 products [22]. Analysis of the predicted amino acid
sequence of the segment 7 ORF1/2 product in this study
showed that it contains 3 leucine-rich segments
(44LDLLRDQVDSL54,  67LDPGLYPWL75,  113LEFSLGL119).
Similar sequences have been suggested to be essential for
proper functioning of the influenza nuclear export protein
(NEP) nuclear export signal [23], and leucine-rich nuclear
export signals (LxxLxxLxLxL) have been described for
other viral proteins such as HIV Rev [24]. We therefore
speculate that the segment 7 ORF1/2 (18-kDa) protein is
the putative ISAV NEP.
Identification of a third functional ORF in ISAV segment 7
The rabbit antiserum against the GST-7 ORF1 fusion pro-
tein was also used to directly monitor the synthesis of the
7-ORF1 protein in ISAV-infected cells in cell culture. For
this, TO cell monolayers were infected with ISAV isolate
RPC/NB 980-049-1 at a multiplicity of infection of 10 and
individual flasks were removed daily from 1–5 days and
were radiolabeled for 20 hr with 100 μCi of [35S]methio-
nine. The cell monolayers were then harvested using RIPA
buffer and were then subjected to immunoprecipitation
with the rabbit antiserum against the GST-7 ORF1 fusion
protein. Four individual protein bands of 68, 32, 18, and
10.6 kDa were detected in ISAV-infected cell lysates but
not in uninfected cell controls (Fig. 6). The 68-kDa band
corresponds to the ISAV NP protein [7]; cross-reactivity
with the antiserum against GST-7 ORF1 fusion protein
was surprising since there is no amino acid sequence
homology between NP and 7-ORF1 proteins. It is possible
Table 2: Immunofluorescence of ASK-2 cell cultures infected with ISAV and stained with rabbit antiserum to GST-7ORF1 fusion 
protein.
Days post-inoculation with ISAV 
RPC/NB 980-049-1
ASK-2 cell line TO cell line CHSE-214 cell line
1 C-, IF± C-, IF- C-, IF-
3 C+++, IF+++ C+, IF+ C-, IF-
6 C++++++, IF++++++ C++++, IF+++++ C-, IF±
CPE (C)
Immunofluorescence (IF)
Table 3: Relative percent survival (RPS) of ISAV vaccines in Atlantic salmon using two different challenge doses
ISAV vaccine, and number of fish used Total mortality (%) RPSa
High challenge dose of 106.1 TCID50/fish
GST-Seg 6, 46 fish 12 (26.1%) 67.5%
GST-Seg 7 ORF1, 46 fish 14 (30.4%) 62.2%
GST in BL21 E. coli, 45 fish 14 (31.1%) 61.3%
Unvaccinated fish, 46 fish 37 (80.4%) 0.0%
Low challenge dose of 103.5 TCID50/fish
GST-Seg 6, 46 fish 21 (45.6%) 41.8%
GST-Seg 7 ORF1, 43 fish 11 (25.6%) 67.3%
GST in BL21 E. coli, 43 fish 8 (18.6%) 76.2%
Unvaccinated fish, 46 fish 36 (78.3%) 0.0%
aCalculation of RPS is an accepted method of determining the effectiveness of a vaccine [44]. RPS = [1-(% mortality of test group ÷ % mortality of 
control group)] × 100%.Virology Journal 2007, 4:34 http://www.virologyj.com/content/4/1/34
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Percent cumulative mortality of Atlantic salmon vaccinated with different vaccine preparations and then challenged with ISAV  isolate NBISA01 Figure 5
Percent cumulative mortality of Atlantic salmon vaccinated with different vaccine preparations and then chal-
lenged with ISAV isolate NBISA01. (A) Vaccinated fish challenged with low challenge dose (103.5 TCID50/0.2 ml/fish). (B) 
Vaccinated fish challenged with high challenge dose (106.0 TCID50/0.2 ml/fish).
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that the two proteins have a similar conformation
epitope. We have noted a similar cross-reactivity with a
monoclonal antibody against the ISAV NP protein [25].
The 32-kDa protein was immunoprecipitated from lysates
of the ISAV-infected TO cells throughout the sampling
period (Fig. 6, lanes 2–6); the protein is comparable in
size to that immunoprecipitated from ISAV-infected TO
cell lysates using antiserum against purified ISAV (Fig. 2B,
lanes 2–4). Thus the molecular mass of 35 kDa for the
viral protein in the purified virus (Fig. 3C, lane 1) is larger
than the segment 7 ORF1 in the infected cells and the in
vitro transcription-translation product, and we consider
this additional evidence for the post-translational modifi-
cations of the mature segment 7 ORF 1 protein. The 18-
kDa protein was seen only at 1 and 2 days (Fig. 6, lanes 2–
3) whereas the 10.6 kDa protein was present only at day 2
(Fig. 6, lane 3) of sampling. We speculate that these two
proteins are also encoded by ISAV segment 7 and the
cross-reactivity with the GST-7 ORF1 antiserum is because
they share the N-terminal 22 amino acids of the 7-ORF1
protein. Previously, only the segment 7 ORF2 product was
suggested to have this sequence [10], and would corre-
spond to the 18-kDa protein in our study. We now show
for the first time that a third protein of 10.6 kDa may have
similar sequence. This spliced protein would consist of
the first 22 amino acids of the 7-ORF1 product and a 257
nucleotide intron spliced out so that the translation con-
tinues in the +3 reading frame for a total of 81 amino
acids (aa), and a predicted molecular weight of 9.5 kDa.
This is a new putative ISAV protein never before reported,
as a result of which we have also proposed a new gene
expression model of ISAV segment 7 (Fig. 7), distinct from
the coding strategy of segment 7 of influenza A virus.
Analysis of 10 ISAV isolates for which we have full-length
sequences of the 7-ORF1 gene, ISAV isolates RPC/NB 98-
049-1, RPC/NB 02-1179-4, RPC/NB 98-0280-2, RPC/NB
02-0775-14, 7833-1, RPC/NB 01-0593-1, RPC/NB 01-
0973-3, RPC/NB 04-085-1, 485/9/97, and 390/98
revealed that the segment 7-ORF1/3 polypeptide of 81 aa
is present in all ISAV isolates of the North American gen-
otype, whereas it terminates after 62 or 32 aa in ISAV iso-
lates of the European genotype (Table 4).
Conclusion
Several conclusions can be summarized: (i) Although a
detailed analysis of all the ISAV proteins is not the primary
subject of this communication, it is apparent that the ISAV
genome, like the influenza A virus genome [26], encodes
at least nine structural proteins but the gene order and
putative functional identities of the ISAV proteins are sig-
nificantly different from those of influenza viruses. (ii)
We have provided a revised gene expression model of
ISAV segment 7 together with evidence suggesting that
segment 7 encodes 3 proteins. (iii) We have identified and
characterized the protein encoded by segment 7 ORF1 as
a 35-kDa minor structural protein of ISAV. (iv) Addition-
ally, we show that vaccination of farmed Atlantic salmon
with the segment 7 ORF1 protein resulted in a moderate
protection against a severe ISAV challenge. (v) Based on
the presence of nuclear export signals in the protein
encoded by segment 7 ORF1/2, we have identified it as the
putative ISAV nuclear export protein. (vi) The segment 7
ORF1/3 is a new protein of unknown function which is 81
amino   acids in ISAV of North American genotype but ter-
minates after 62   or 32 aa in ISAV isolates of the European
genotype. We are   presently studying these proteins to
determine their functional roles   in ISAV.
Autoradiograph of SDS-PAGE of expressed proteins labeled  with [35S]methionine in TO cells infected with ISAV, immu- noprecipitated with rabbit antiserum to GST-7ORF1 fusion  protein Figure 6
Autoradiograph of SDS-PAGE of expressed proteins 
labeled with [35S]methionine in TO cells infected 
with ISAV, immunoprecipitated with rabbit antise-
rum to GST-7ORF1 fusion protein. The prestained pro-
tein standards (Invitrogen Life Sciences) are drawn in on the 
left while corresponding molecular masses of immunoprecip-
itated ISAV proteins are indicated on the right. Lanes 1 to 6 
contain radiolabeled proteins synthesized in uninfected TO 
cells, ISAV-infected TO cells at 1–5 days post-infection, 
respectively.Virology Journal 2007, 4:34 http://www.virologyj.com/content/4/1/34
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Methods
Cells, viruses, and virus culture
TO cells [27] and ASK-2 cells [28] are continuous fish
macrophage-like cell lines originally derived from Atlantic
salmon head kidney leukocytes. TO cells were grown in
HMEM [Eagle's minimum essential medium containing
Hank's salts and sodium bicarbonate (0.2 g/L) BioWhit-
taker Inc., Walkersville, Maryland, USA] supplemented
with 292 mM L-glutamine (Sigma), 1% non essential
amino acids (Sigma), 100 μg ml-1 gentamicin (Sigma)
and 10% fetal bovine serum (FBS). ASK-2 cells were
grown in Leibovitz L-15 medium supplemented with 10%
FBS, 2 mM L-glutamine, 100 IU/ml penicillin G, 100 μg
ml-1 streptomycin, and 0.25 μg ml-1 amphotericin B.
Both cell lines were incubated at room temperature
(24°C) and the monolayer cultures were used 24 hrs after
seeding. CHSE-214 cells [29] were grown at 16°C in
HMEM [Eagle's minimum essential medium containing
Hank's salts] (Invitrogen Life Technologies) as previously
described [17]. The source and genotype of the ISAV iso-
lates used in this study are summarized in Table 5. The
viruses were propagated and titrated in TO cells as previ-
ously described [30] prior to use. The viruses were pas-
saged once in ASK-2 cells or CHSE-214 cells before use in
the respective cell lines.
Construction of in-vitro transcription plasmids containing 
ISAV cDNA
The oligonucleotide primers (Table 1) spanning the ORFs
in the eight RNA segments were designed from publicly
Table 4: Open reading frames of RNA segment 7 of selected ISAV isolates
ISAV isolate ISAV genotype1 GenBank Accession Number Seg. 7-ORF1 Seg. 7-ORF1/2 Seg. 7-ORF1/3
RPC/NB 98-049-1 North American, HPR21 EF523761 1–9032 1–66/593–1006 1–66/324–503
RPC/NB 02-1179-4 North American, HPR21 EF523762 1–903 1–66/593–1006 1–66/324–503
RPC/NB 98-0280-2 North American, HPR20 AF401083 1–903 1–66/593–1006 1–66/324–503
RPC/NB 02-0775-14 North American, HPR21 DQ673253 1–903 1–66/593–1006 1–66/324–503
7833-1 North American, HPR21 AF401082 1–903 1–66/593–1006 1–66/324–503
RPC/NB 01-0593-1 North American, HPR21 EF523764 1–903 1–66/593–1006 1–66/324–503
RPC/NB 01-0973-3 North American, HPR21 EF523765 1–903 1–66/593–1006 1–66/324–503
RPC/NB 04-085-1 European, new HPR EF432566 1–903 1–66/593–1006 1–66/324–446
485/9/97 European, HPR14 DQ673254 1–903 1–66/593–1006 1–66/324–362
390/98 European, HPR7 EF523763 1–903 1–66/593–1006 1–66/324–362
1Genotype of ISAV (unpublished results, F. S. B. Kibenge, M. J. T. Kibenge, Y. Wang, B. Qian, S. Hariharan, and S. McGeachy); HPR groups denote 
grouping based on amino acid sequences in the highly polymorphic region (HPR) of the ISAV haemagglutinin-esterase gene as reported by Nylund et 
al. [45] and Plarre et al. [46].
2Numbers refer to nucleotide positions of respective ORF.
New gene expression model for segment 7 of ISAV of North American genotype Figure 7
New gene expression model for segment 7 of ISAV of North American genotype. There are 3 ORFs consisting of 
the primary transcript (7-ORF1) 300 amino acids long, and 7-ORF1/2 and 7ORF1/3 each with an intron removed from 7-ORF1 
and consisting of 159 and 81 amino acids, respectively.Virology Journal 2007, 4:34 http://www.virologyj.com/content/4/1/34
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available ISAV genome sequences in the GenBank data-
base, and were purchased from a commercial source (Inv-
itrogen Life Technologies). For segments 1, 2, and 3,
overlapping RT-PCR products were initially generated and
then used to obtain the complete ORFs. For the purpose
of evaluating individual ORFs, we separated the otherwise
partial overlapping ORFs of segment 7 based on the gene
expression model suggested by Ritchie et al. [10], of par-
tial splicing of ORF1 mRNA and a frameshift such that
ORFs 1 and 2 products share the first 22 amino acid resi-
dues. The RT-PCR amplification of viral cDNA and clon-
ing and nucleotide sequencing procedures used in this
study were previously described [30]. Thus the PCR prod-
ucts were cloned into the pCR®II vector having dual pro-
moters T7 and SP6 in opposite orientation (Invitrogen
Life Technologies) for in vitro coupled transcription and
translation (TNT-Promega) reactions. Plasmids were
sequenced to check for correct orientation and to verify
each viral cDNA sequence.
Cell-free transcription-translation
The pCR®II-TOPO® recombinant plasmids were used as
circular DNA templates. Approximately 1 μg each of plas-
mid DNA was transcribed directly in a translation mix
containing 20 μCi of [35S]methionine (Amersham Phar-
macia Biotech) in 50 μl-reaction volumes using the in vitro
transcription-translation TNT™ T7/SP6 Coupled Reticulo-
cyte Lysate System (TNT-RLS, Promega) as per the manu-
facturer's instructions. A Luciferase DNA (supplied by
Promega) was used as positive control. Following incuba-
tion of the reactions for 90 min at 30°C, 5 μl of each reac-
tion were mixed with 20 μl of 2× Laemmli sample
treatment buffer (0.125 M Tris-HCl pH 6.8, 4% SDS, 20%
glycerol, 0.002% bromophenol blue, 4% 2-mercaptoeth-
anol) [31] and heated at 60°C for 20 min to denature the
proteins. Ten microliters of the denatured sample were
resolved on discontinuous SDS-12-5% PAGE [32] and
radiolabeled proteins in dried gels were visualized by
autoradiography for 48 h at room temperature. The
molecular weights of the proteins were calculated from
the gels using standard procedures [33]. To examine for
glycosylation, a general protocol recommended by the
manufacturer for translation in the TNT-RLS with canine
microsomal membranes (Roche Molecular Biochemicals)
was followed and samples were analyzed by 12.5% SDS-
PAGE and autoradiography.
Construction of pGEX expression plasmid and preparation 
of GST fusion protein
The pCR®II-TOPO® recombinant plasmids, pCR TOPO-
Seg7ORF1 and pCR TOPO-Seg6ORF were used as the
source of the ISAV segment 7 ORF1 and segment 6 ORF,
respectively. PCR was performed using the DeepVent
DNA polymerase (New England Biolabs) as specified in
the manufacturer's protocol. The PCR products were sub-
cloned into the pGEX-5X-2 expression vector (Amersham
Biosciences) to produce constructs pGEX5X2-7ORF1 and
pGEX5X2-6ORF. These constructs were designed to gener-
ate the full-length ISAV segment 7 ORF1 polypeptide and
the ISAV HE polypeptide, respectively, each fused with
GST at its N-terminus, and this was verified by DNA
sequencing.
The plasmid constructs were used to transform competent
E. coli strain BL21(DE3)(pLysS) (Novagen) in order to
express the GST fusion proteins. Transformants were cul-
tivated on LB (Luria-Bertani) broth agar medium contain-
ing 100 μg ml-1 ampicillin. An overnight LB broth culture
Table 5: Origin and genotype of different ISAV isolates
Isolate and geographic origin Laboratory source1 and Year of isolation ISAV genotype2
NBISA01, NB, Canada Aqua Health, 1998 North American, HPR21
RPC/NB 98-049-1, NB, Canada RPC, 1998 North American, HPR21
RPC/NB 98-0280-2, NB, Canada RPC, 1998 North American, HPR20
7833-1, Chile Aquatic Health, 1999 North American, HPR21
RPC/NB 01-0593-1, NB, Canada RPC, 2001 North American, HPR21
RPC/NB 02-0973-3, NB, Canada RPC, 20021 North American, HPR21
RPC/NB 02-0775-14, NB, Canada RPC, 2002 North American, HPR21
RPC/NB 02-1179-4, NB, Canada RPC, 2002 North American, HPR21
485/9/97, Norway B. Dannevig, 1997 European, HPR14
810/9/99, Norway B. Dannevig, 1999 European, HPR15
U5575-1, NS, Canada AVC, 2000 European, HPR3
RPC/NB 04-085-1, NB, Canada RPC, 2004 European, new HPR
1Sources of isolates were: Aqua Health Ltd, Charlottetown, PEI, Canada; RPC, Research and Productivity Council, Fredericton, NB, Canada; B. 
Dannevig, National Veterinary Institute, Oslo, Norway; A. McVicar, Fish Health Inspectorate, FRS, Marine Laboratories, Aberdeen, UK; Aquatic 
Health, Chile Ltd, Puerto Mont, Chile; AVC, Atlantic Veterinary College Regional Diagnostic Virology Laboratory.
2Genotype of ISAV (unpublished results, F. S. B. Kibenge, M. J. T. Kibenge, Y. Wang, B. Qian, S. Hariharan, and S. McGeachy); HPR groups denote 
grouping based on amino acid sequences in the highly polymorphic region (HPR) of the ISAV haemagglutinin-esterase gene as reported by Nylund et 
al. [45] and Plarre et al. [46].Virology Journal 2007, 4:34 http://www.virologyj.com/content/4/1/34
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of the transformant was pelleted by centrifugation,
washed with LB medium (10 g/L bactotryptone, 5 g/L
yeast extract, and 5 g/L NaCl, adjusted to pH 7.4) contain-
ing 200 μg ml-1 ampicillin and diluted 100× in 2-4L of LB
medium supplemented with 2 g/L dextrose and 150 μg
ml-1 ampicillin and grown at 37°C with agitation (165
rpm). When the optical density reached a value of 0.7 at
600 nm, protein expression was induced at 15°C by addi-
tion of IPTG (Amersham Biosciences) to a final concentra-
tion of 0.1 mM. Cells were harvested by centrifugation at
6,000 g for 12 min at 4°C and resuspended in 40 ml PBS
(150 mM NaCl, 16 mM Na2HPO4, and 4 mM NaH2PO4,
pH 7.3). This step was repeated twice to wash the cells.
The supernatant was discarded and the wet cell paste was
frozen at -20°C overnight. The bacterial cells were
thawed, re-suspended in lysis buffer containing 50 mM
Tris pH 8.0, 500 mM NaCl, 1 × BugBuster protein extrac-
tion reagent (Novagen), 1 mM DTT, 10% glycerol, 300 μg
ml-1 lysozyme, 1 mM PMSF, Complete protease inhibitor
(Roche Applied Science), and incubated with stirring for 2
h at 4°C. Then, Benzonase nuclease (Novagen) was added
as specified by the supplier, incubated with slow stirring
at 4°C for 1 h. The cells were centrifuged at 10,000 g for 1
h. The supernatants were collected and filtered using 0.45
μm filters (Gelman Sciences) for affinity chromatography
purification. The GST-7ORF1 fusion protein and the GST-
HE fusion protein contained in the supernatants were sep-
arately purified by affinity chromatography using Glu-
tathione Sepharose (Amersham Biosciences) batch
method at 4°C according to the manufacturer's protocol.
The final elutes of each fusion protein were pooled, con-
centrated and desalted using Centricon-Plus 20 (Amicon).
The concentration of each fusion protein was estimated
roughly by spectrophotometry at 280 nm where 1A = 0.5
mg/ml GST fusion protein, and its purity and integrity
were analyzed by resolving it on discontinuous SDS-
12.5% PAGE [32] and visualized with Coomassie Blue R-
250 (Bio-Rad). The BL 21 strain of E. coli without ISAV
gene was lysed with 0.5% NP-40 (Sigma) and then clari-
fied at 700 g to obtain the bacterial lysate without ISAV
proteins.
Rabbit antiserum production
Preparation of rabbit polyclonal antiserum to purified
ISAV isolate RPC/NB 980 049-1 has been described [15].
Rabbit polyclonal antiserum to GST-7 ORF1 fusion pro-
tein was prepared using a similar procedure. Briefly, GST-
7 ORF1 fusion protein inclusion bodies were resuspended
in Arginine buffer (10 mM Tris-HCl, 150 mM NaCl, 800
mM L-Arginine, pH 8.5). Two hundred and fifty microlit-
ers of the suspension were brought to 1.25 ml with PBS
and were then aliquoted into 250 μl-volumes. One 250 g
rabbit (Charles River Canada) was inoculated subcutane-
ously five times at 3-week intervals with 250 μl of the GST-
7 ORF1 fusion protein, once mixed with an equal volume
of Freund's complete adjuvant and four times in Freund's
incomplete adjuvant. Pre-inoculation serum and sera col-
lected every 3 weeks until after the last injection were
tested for the presence of antibodies against purified ISAV
by Western blot analysis.
Fish vaccination assay
Specific pathogen-free Atlantic salmon parr (St. John River
stock) were obtained either from the Cardigan Fish Hatch-
ery, Cardigan, P.E.I. or Atlantic Sea Smolt Ltd., Souris,
P.E.I., Canada. The average weight of the fish at the start
of the trial was 9.1 gm in the freshwater phase. An oppor-
tune sample of five fish was screened for ISAV by virus iso-
lation attempts from tissue samples (kidney, heart,
spleen, pyloric caeca) on the TO cell line and monitoring
for CPE and RT-PCR [30] to establish the ISAV-negative
status of the stock before the vaccination. The fish were
maintained in the Aquatic Animal Facility of the Atlantic
Veterinary College (AVC) in 1 m diameter fibreglass-rein-
forced plastic tanks using a freshwater flow through sys-
tem at a temperature of approximately 11°C. The fish
were acclimatized in freshwater for 2 weeks at a water flow
rate of 3.5 L/min. The experimental procedures used in
this study were performed in accordance with the guide-
lines of the Canadian Council of Animal Care [34].
The fish were divided into groups: the unvaccinated group
consisted of 187 fish in one tank while each of the vacci-
nated groups consisted of 43–46 fish per tank in two
tanks. For the vaccination, the fish were removed from the
stock holding tank and anaesthetized by immersion in an
aerated solution of tricaine methane sulphonate (TMS-
222) (100 mg/L). The vaccination consisted of an intra-
peritoneal injection with a vaccine dose of 50 μg/0.2 ml/
fish and the fish was then returned to the respective study
tank. The fish were held for 56 days and then each vacci-
nated group was challenged with ISAV isolate NBISA01
using two different doses for each two tanks; a high dose
(106.1 TCID50) and a low dose (103.5 TCID50). For this
challenge trial, the fish in the unvaccinated tank were
divided into three groups: two groups consisted of 46 fish
in each tank to serve as the unvaccinated challenged con-
trols for the high and low challenge doses while the
remaining 95 fish were moved to an uninfected control
tank which was located in a separate "clean" room away
from the tanks with the vaccinated fish. For the experi-
mental infection, the challenge fish were removed from
the respective tank and anaesthetized as before. Each fish
was then challenged by the intraperitoneal route with 0.2
ml of virus suspension of the high dose or low dose of
ISAV and was then returned to the respective study tank.
Caution was taken to avoid contact between the tanks for
the two different challenge doses. Fish were fed once eve-
ryday and the fish tanks were flushed once a day. All tanks
were checked twice daily for mortality, the fish wereVirology Journal 2007, 4:34 http://www.virologyj.com/content/4/1/34
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observed for abnormal behaviour, and external lesions
until the study was terminated at 42 days post challenge.
All dead fish were necropsied and, where necessary, tis-
sues (kidney, heart, spleen, pyloric caeca) were collected
for virus detection by reverse transcriptase PCR (RT-PCR)
amplification and histopathology.
Pulse labeling infected cells with [35S]methionine
The TO, ASK-2, and CHSE-214 cells in 4-well tissue cul-
ture plates or 25 cm2 tissue culture flasks were infected
with ISAV at a multiplicity of infection of 10, and labeled
with [35S]methionine as described previously [15,35],
with slight modifications. Briefly, at 1, 2, 3, 4, 5, and 6
days post-infection, monolayers were washed twice with
cold phosphate buffered saline (PBS), pH 7.2, and were
incubated in 1 ml/well methionine-free EMEM supple-
mented with 5% dialyzed FBS to deplete residual methio-
nine. After 2.5 h, cells were radiolabeled for 20 h with
100–200  μCi of [35S]methionine (specific activity
approximately 1000 Ci/mmol at 10 μCi/μl; Amersham
Pharmacia Biotech) in 1–2 ml methionine-free EMEM
containing 5% dialyzed FBS. To obtain labeled cells, the
medium was aspirated and cells were washed twice with
PBS and then lysed with 500 μl RIPA buffer (150 mM
NaCl, 1% sodium deoxycholate, 1% aprotinin, 1% Triton
X-100, 1% sodium dodecyl sulfate, 10 mM Tris-HCl, pH
7.2). The lysate was centrifuged at 12,000 g for 2 min and
the supernatant was transferred to a fresh microfuge tube
and stored at -20°C until used.
Immunoprecipitation of polypeptides
ISAV proteins synthesized in ISAV-infected cells or by in
vitro  transcription-translation system were analyzed by
immunoprecipitation with rabbit antiserum to purified
ISAV isolate RPC/NB-980 049-1 prepared as described
previously [15]. The immunoprecipitation was carried out
as described by Sambrook et al. [36], with slight modifica-
tions. Briefly, the 10 μl of cell lysates or in vitro translation
sample brought to 500 μl total volume in NET-gel buffer
(150 mM NaCl, 0.1% Nonidet P-40, 1 mM EDTA, pH 8.0,
0.25% gelatin, 0.02% sodium azide, 50 mM Tris-HCl, pH
7.5) were initially precleared with pre-immune rabbit
serum and Protein-A Sepharose beads (Sigma) to reduce
non-specific background. For the specific immunoprecip-
itations, each precleared supernatant was reacted with 20
μl of rabbit hyper-immune antiserum at 0°C for 1 h. Each
mixture was then reacted with Protein-A Sepharose beads
at 4°C for 1 h. The Sepharose beads were washed with 10
mM Tris-HCl, pH 7.5, 0.1% NP-40, mixed with 30 μl of
2× SDS sample loading buffer, and heated at 100°C for 5
min prior to fractionation on discontinuous SDS-12-5%
PAGE [32]. Radiolabeled proteins in dried gels were visu-
alized by autoradiography for 48 h at room temperature.
Gel electrophoresis of viral proteins and Western blot 
analysis
Samples were mixed with an equal volume of 2× SDS
sample loading buffer, and heated at 100°C for 5 min
prior to fractionation on discontinuous SDS-12-5% PAGE
(Laemmli 1971). Proteins were visualized with Coomas-
sie blue R-250 (Bio-Rad). Duplicate gels were used in
Western blotting as described previously [17]. Briefly,
resolved proteins in unstained gels were transferred from
the gel to the nitrocellulose membranes using a Trans-Blot
apparatus (Bio-Rad) for 4 hr at 60 V (65 mA/cm2). The
membranes were blocked with PBS containing 3% skim
milk and then reacted with a 1:50 dilution of rabbit
antiserum to GST-7 ORF1 fusion protein or to purified
ISAV isolate RPC/NB-980 049-1. The blots were reacted
with a 1:30,000 dilution of goat anti-rabbit alkaline phos-
phatase conjugate (Sigma) and colour was developed
with BCIP/NBT substrate (Bio-Rad).
DNA sequencing and analysis of sequence data
Plasmid DNA for sequencing was prepared as described
before [37]. Denatured plasmid DNA was sequenced
using the ABI BIG DYE terminator version 3.1 cycle
sequencing kit (Applied Biosystems, Inc.) and the MJ
Research thermal cycler. Sequencing reactions were
resolved on two DNA sequencers. The first, a model 377
ABI Prism Automated DNA Sequencer (Applied Biosys-
tems, Inc.) using 36–64 lanes on a 48 cm plate. ABI's
'mobility file' that comes with the dye terminator kit was
used to correctly call the bases. The electropherograms
were inspected and edited using "Sequencing Analysis
3.3" software provided with the 377 Prism by ABI. The
second, a model 3100 ABI Genetic Analyzer (Applied Bio-
systems, Inc.) with a 50 cm – 16 capillary array using POP-
6 polymer. ABI's 'mobility file' that comes with the dye
terminator kit was used to correctly call the bases. The
electropherograms were inspected and edited using
"Sequencing Analysis 5.1.1" software provided with the
3100 ABI Genetic Analyzer. Sequence analysis used the
BLAST programs [38], the Sequence Manipulation suite
[39], and the FASTA program package for microcomputers
[40]. The following programs available through ExPASy
Molecular Biology Server [41] were also utilized: Scan-
Prosite, MotifScan, PROSCAN, SignalP. V1.1, and
TMHMM server v. 2.0 [18,42]. The ProtScale program was
accessed via the Sanger web site [43].
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